UBS AM’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.77M Sell
154,186
-34,116
-18% -$477K ﹤0.01% 1917
2026
Q1
$1.77M Sell
188,302
-7,885
-4% -$86.6K ﹤0.01% 2095
2025
Q4
$2.44M Sell
196,187
-6,769
-3% -$90K ﹤0.01% 1807
2025
Q3
$2.91M Sell
202,956
-105,183
-34% -$1.44M ﹤0.01% 1605
2025
Q2
$3.78M Buy
308,139
+63,804
+26% +$926K ﹤0.01% 1835
2025
Q1
$5.37M Buy
244,335
+45,693
+23% +$1.07M ﹤0.01% 1532
2024
Q4
$4.51M Buy
198,642
+28,457
+17% +$621K ﹤0.01% 1656
2024
Q3
$3.09M Sell
170,185
-466
-0.3% -$10.8K ﹤0.01% 1804
2024
Q2
$4.97M Buy
170,651
+53,412
+46% +$1.58M ﹤0.01% 1492
2024
Q1
$4.16M Sell
117,239
-257
-0.2% -$10.3K ﹤0.01% 1338
2023
Q4
$5.12M Hold
117,496
﹤0.01% 1231
2023
Q3
$4.49M Buy
117,496
+1,334
+1% +$56.1K ﹤0.01% 1253
2023
Q2
$6.67M Hold
116,162
﹤0.01% 1112
2023
Q1
$6.67M Buy
116,162
+15,512
+15% +$874K ﹤0.01% 1112
2022
Q4
$5.64M Buy
100,650
+8,741
+10% +$445K ﹤0.01% 1129
2022
Q3
$3.89M Sell
91,909
-22,360
-20% -$1.15M ﹤0.01% 1288
2022
Q2
$6.17M Buy
114,269
+1,936
+2% +$116K ﹤0.01% 1138
2022
Q1
$7.22M Buy
112,333
+6,995
+7% +$461K ﹤0.01% 1195
2021
Q4
$7.06M Sell
105,338
-2,967
-3% -$201K ﹤0.01% 1255
2021
Q3
$7.42M Buy
108,305
+510
+0.5% +$36K ﹤0.01% 1204
2021
Q2
$7.36M Buy
107,795
+1,836
+2% +$130K ﹤0.01% 1221
2021
Q1
$7.32M Sell
105,959
-11,034
-9% -$748K ﹤0.01% 1191
2020
Q4
$7.6M Buy
116,993
+15,896
+16% +$855K ﹤0.01% 1146
2020
Q3
$4.77M Buy
101,097
+5,509
+6% +$262K ﹤0.01% 1162
2020
Q2
$4.49M Sell
95,588
-2,573
-3% -$126K ﹤0.01% 1159
2020
Q1
$4.38M Buy
98,161
+9,486
+11% +$498K ﹤0.01% 1091
2019
Q4
$5.17M Sell
88,675
-9,388
-10% -$559K ﹤0.01% 1172
2019
Q3
$5.89M Buy
98,063
+11,582
+13% +$690K ﹤0.01% 1144
2019
Q2
$4.83M Buy
86,481
+5,040
+6% +$260K ﹤0.01% 1216
2019
Q1
$4.54M Buy
81,441
+5,436
+7% +$277K ﹤0.01% 1189
2018
Q4
$3.43M Buy
76,005
+5,057
+7% +$277K ﹤0.01% 1218
2018
Q3
$4.67M Buy
70,948
+3,691
+5% +$229K ﹤0.01% 1161
2018
Q2
$4.33M Buy
67,257
+13,811
+26% +$855K ﹤0.01% 1209
2018
Q1
$2.96M Buy
53,446
+5,917
+12% +$310K ﹤0.01% 1310
2017
Q4
$2.27M Buy
47,529
+2,745
+6% +$134K ﹤0.01% 1379
2017
Q3
$2.26M Buy
44,784
+1,753
+4% +$90K ﹤0.01% 1351
2017
Q2
$2.35M Buy
43,031
+3,124
+8% +$149K ﹤0.01% 1298
2017
Q1
$1.68M Sell
39,907
-5,449
-12% -$233K ﹤0.01% 1417
2016
Q4
$1.95M Sell
45,356
-12,998
-22% -$528K ﹤0.01% 1298
2016
Q3
$2.41M Sell
58,354
-6,974
-11% -$292K ﹤0.01% 1307
2016
Q2
$2.6M Sell
65,328
-18,852
-22% -$678K ﹤0.01% 1260
2016
Q1
$2.83M Sell
84,180
-6,198
-7% -$193K ﹤0.01% 1225
2015
Q4
$3.06M Buy
90,378
+1,588
+2% +$49.6K ﹤0.01% 1242
2015
Q3
$2.64M Buy
88,790
+6,968
+9% +$218K ﹤0.01% 1297
2015
Q2
$2.25M Sell
81,822
-11,102
-12% -$296K ﹤0.01% 1352
2015
Q1
$2.34M Sell
92,924
-1,564
-2% -$37K ﹤0.01% 1298
2014
Q4
$2.1M Buy
94,488
+75,650
+402% +$1.53M ﹤0.01% 1305
2014
Q3
$382K Hold
18,838
﹤0.01% 2012
2014
Q2
$362K Hold
18,838
﹤0.01% 2075
2014
Q1
$354K Buy
18,838
+1,468
+8% +$28.3K ﹤0.01% 2075
2013
Q4
$339K Sell
17,370
-1,468
-8% -$26.9K ﹤0.01% 2041
2013
Q3
$310K Hold
18,838
﹤0.01% 2065
2013
Q2
$282K Buy
+18,838
New +$276K ﹤0.01% 2032

Other funds holding IART

UBS AM's IART Position: Q2 2026 in Review

UBS AM reduced its Integra LifeSciences (IART) stake by 18% in Q2 2026, selling an estimated $477K and leaving 154,186 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

UBS AM first reported a position in IART in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.6M in Q4 2020. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • UBS AM held 154,186 shares of Integra LifeSciences worth $2.77M as of Q2 2026.
  • UBS AM sold 34,116 Integra LifeSciences shares in Q2 2026, an estimated $477K.
  • Integra LifeSciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1917 holding.
  • UBS AM first reported a position in Integra LifeSciences in Q2 2013 and has held it in 53 quarters since.
  • UBS AM's Integra LifeSciences position peaked at $7.6M in Q4 2020.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.